Unusual 11 Mid-Day Movers 5/27: SPF, GFG, QTWW, JMBA Higher; FVRL, UBS, FTK, XFML Lower May 27, 2008 12:23PM

Favrille, Inc. (Nasdaq: FVRL) 85.8% LOWER; announced results from the Company's Phase 3 registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma. Analysis of time to progression, the primary endpoint in the trial, failed to show a statistically significant improvement in the treatment arm, Specifid plus Leukine following Rituxan, compared to the control arm, placebo plus Leukine following Rituxan. Analysis of all subgroups also did not show any significant differences in primary or secondary endpoints when adjusted for ...